Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 932615, 13 pages
http://dx.doi.org/10.1155/2014/932615
Research Article

Prolonged Hypocalcemic Effect by Pulmonary Delivery of Calcitonin Loaded Poly(Methyl Vinyl Ether Maleic Acid) Bioadhesive Nanoparticles

1Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, P.O. Box 81745-359, Isfahan 81746-73461, Iran
2Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran

Received 9 September 2013; Revised 8 December 2013; Accepted 12 January 2014; Published 20 February 2014

Academic Editor: Fabio Sonvico

Copyright © 2014 J. Varshosaz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Andreotti, B. L. Méndez, P. Amodeo, M. A. Castiglione Morelli, H. Nakamuta, and A. Motta, “Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic α-helix,” Journal of Biological Chemistry, vol. 281, no. 34, pp. 24193–24203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. L. W. Kline and G. A. Longmore, “Determination of calcitonin in reptilian serum by heterologous radioimmunoassay,” General and Comparative Endocrinology, vol. 61, no. 1, pp. 1–4, 1986. View at Google Scholar · View at Scopus
  3. S. E. Wendelaar Bonga and P. K. T. Pang, “Control of calcium regulating hormones in the vertebrates: parathyroid hormone, calcitonin, prolactin, and stanniocalcin,” International Review of Cytology, vol. 128, pp. 139–213, 1991. View at Google Scholar · View at Scopus
  4. L. Thomas, Clinical Laboratory Diagnostics, TH-Books Verlagsgesellschaft, Framkfurt, Germany, 1st edition, 1998.
  5. D. B. Endres and R. K. Rude, “Mineral and bone metabolism,” in Textbook of Clinical Chemistry, C. A. Burtis and E. R. AShwood, Eds., pp. 1395–1457, W.B Saunders Company, Philadelphia, Pa, USA, 3rd edition, 1999. View at Google Scholar
  6. J. C. Stevenson and I. M. A. Evans, “Pharmacology and therapeutic use of calcitonin,” Drugs, vol. 21, no. 4, pp. 257–272, 1981. View at Google Scholar · View at Scopus
  7. J. M. Hilton, M. Dowton, S. Houssami, and P. M. Sexton, “Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors,” Journal of Endocrinology, vol. 166, no. 1, pp. 213–226, 2000. View at Google Scholar · View at Scopus
  8. P. J. Sinko, C. L. Smith, L. T. McWhorter, W. Stern, E. Wagner, and J. P. Gilligan, “Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats,” Journal of Pharmaceutical Sciences, vol. 84, no. 11, pp. 1374–1378, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Henriksen, A.-C. Bay-Jensen, C. Christiansen, and M. A. Karsdal, “Oral salmon calcitonin pharmacology in osteoporosis,” Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1617–1629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. B. Shah and M. A. Khan, “Regional permeability of salmon calcitonin in isolated rat gastrointestinal tracts: transport mechanism using Caco-2 cell monolayer,” AAPS Journal, vol. 6, no. 4, article 31, pp. 1–5, 2004. View at Google Scholar · View at Scopus
  11. M. A. Karsdal, K. Henriksen, M. Arnold, and C. Christiansen, “Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality,” BioDrugs, vol. 22, no. 3, pp. 137–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. P. John and J. Harald, “Disorders of the parathyroid gland and calcium homeostasis,” in HarriSon'S PrincipleS of Internal Medicine, D. L. Longo, D. L. Kasper, J. L. Jameson, A. S. Fauci, S. L. Hauser, and J. Loscalzo, Eds., McGraw-Hill, 18th edition, 2008. View at Google Scholar
  13. M. Zaidi, A. M. Inzerillo, B. S. Moonga, P. J. R. Bevis, and C.-H. Huang, “Forty years of calcitonin: where are we now? A tribute to the work of Iain Macintyre, FRS,” Bone, vol. 30, no. 5, pp. 655–663, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. L. Carney, “Calcitonin and human renal calcium and electrolyte transport,” Mineral and Electrolyte Metabolism, vol. 23, no. 1, pp. 43–47, 1997. View at Google Scholar · View at Scopus
  15. T. Beveridge, W. Niederer, E. Nüesch, and A. Petrin, “Pharmacokinetic study with synthetic salmon calcitonin (Sandoz),” Zeitschrift für Gastroenterologie, no. 10, pp. 12–15, 1976. View at Google Scholar · View at Scopus
  16. M. Hinchcliffe, I. Jabbal-Gill, and A. Smith, “Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep,” Journal of Pharmacy and Pharmacology, vol. 57, no. 6, pp. 681–687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. S. Youn, M. J. Kwon, D. H. Na, S. Y. Chae, S. Lee, and K. C. Lee, “Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection,” Journal of Controlled Release, vol. 125, no. 1, pp. 68–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Tewes, L. Tajber, O. I. Corrigan, C. Ehrhardt, and A. M. Healy, “Development and characterisation of soluble polymeric particles for pulmonary peptide delivery,” European Journal of Pharmaceutical Sciences, vol. 41, no. 2, pp. 337–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Huwyler, W. Born, E. E. Ohnhaus, and J. A. Fischer, “Plasma kinetics and urinary excretion of exogenous human and salmon calcitonin in man,” The American Journal of Physiology, vol. 236, no. 1, pp. E15–E19, 1979. View at Google Scholar · View at Scopus
  20. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima, “pH-sensitive microsphere delivery increases oral bioavailability of calcitonin,” Journal of Controlled Release, vol. 98, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Y.-H. Lee and P. J. Sinko, “Oral delivery of salmon calcitonin,” Advanced Drug Delivery Reviews, vol. 42, no. 3, pp. 225–238, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Sinswat and P. Tengamnuay, “Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-β-cyclodextrins,” International Journal of Pharmaceutics, vol. 257, no. 1-2, pp. 15–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Morimoto, H. Katsumata, T. Yabuta et al., “Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin,” European Journal of Pharmaceutical Sciences, vol. 13, no. 2, pp. 179–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Torres-Lugo and N. A. Peppas, “Transmucosal delivery systems for calcitonin: a review,” Biomaterials, vol. 21, no. 12, pp. 1191–1196, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-Y. Reginster, I. Jupsin, R. Deroisy, I. Biquet, N. Franchimont, and P. Franchimont, “Prevention of postmenopausal bone loss by rectal calcitonin,” Calcified Tissue International, vol. 56, no. 6, pp. 539–542, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Gennari, S. Gonnelli, G. Monaci, M. S. Campagna, and B. Franci, “Pharmacodynamic activity of synthetic salmon calcitonin in osteoporotic patients: comparison between rectal and intramuscular administration. Pilot study,” Current Therapeutic Research, vol. 53, no. 3, pp. 301–308, 1993. View at Google Scholar · View at Scopus
  27. S. B. Petersen, L. G. Nielsen, U. L. Rahbek, M. Guldbrandt, and D. J. Brayden, “Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer,” European Journal of Pharmaceutical Sciences, vol. 48, no. 4-5, pp. 726–734, 2013. View at Google Scholar
  28. M. Asano, M. Yoshida, H. Omichi et al., “Biodegradable poly(DL-lactic acid) formulations in a calcitonin delivery system,” Biomaterials, vol. 14, no. 10, pp. 797–799, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Millest, J. R. Evans, J. J. Young, and D. Johnstone, “Sustained release of salmon calcitonin in vivo from lactide: glycolide copolymer depots,” Calcified Tissue International, vol. 52, no. 5, pp. 361–364, 1993. View at Google Scholar · View at Scopus
  30. R. V. Diaz, M. Llabrés, and C. Évora, “One-month sustained release microspheres of125I-bovine calcitonin In vitro: in vivo studies,” Journal of Controlled Release, vol. 59, no. 1, pp. 55–62, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Tasset, N. Barette, S. Thysman, J. M. Ketelslegers, D. Lemoine, and V. Préat, “Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin,” Journal of Controlled Release, vol. 33, no. 1, pp. 23–30, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. R. van Dijkhuizen-Radersma, H. M. Nicolas, M. Van de Weert, M. Blom, K. de Groot, and J. M. Bezemer, “Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems,” International Journal of Pharmaceutics, vol. 248, no. 1-2, pp. 229–237, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Tewes, O. L. Gobbo, M. I. Amaro et al., “Evaluation of HPβCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery,” Molecular Pharmaceutics, vol. 8, no. 5, pp. 1887–1898, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Yamada, “Control of pulmonary absorption of drugs by various pharmaceutical excipients,” Yakugaku Zasshi, vol. 127, no. 4, pp. 631–641, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Makhlof, M. Werle, Y. Tozuka, and H. Takeuchi, “Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin,” International Journal of Pharmaceutics, vol. 397, no. 1-2, pp. 92–95, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Clark, M.-C. Kuo, S. Newman, P. Hirst, G. Pitcairn, and M. Pickford, “A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin,” Pharmaceutical Research, vol. 25, no. 7, pp. 1583–1590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, and Y. Kawashima, “Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions,” Journal of Controlled Release, vol. 102, no. 2, pp. 373–381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Yang, S. Velaga, H. Yamamoto et al., “Characterisation of salmon calcitonin in spray-dried powder for inhalation: effect of chitosan,” International Journal of Pharmaceutics, vol. 331, no. 2, pp. 176–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Arbós, M. A. Campanero, M. A. Arangoa, M. J. Renedo, and J. M. Irache, “Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties,” Journal of Controlled Release, vol. 89, no. 1, pp. 19–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Yoncheva, E. Lizarraga, and J. M. Irache, “Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties,” European Journal of Pharmaceutical Sciences, vol. 24, no. 5, pp. 411–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. C. M. Gardner, N. A. D. Burke, T. Chu, F. Shen, M. A. Potter, and H. D. H. Stöver, “Poly(methyl vinyl ether-alt-maleic acid) polymers for cell encapsulation,” Journal of Biomaterials Science, vol. 22, no. 16, pp. 2127–2145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. I. Camacho, R. Da Costa Martins, I. Tamayo et al., “Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators,” Vaccine, vol. 29, no. 41, pp. 7130–7135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. C. W. Lin, Y. F. Huang, and A. M. Kannan, “Semi-interpenetrating network based on cross-linked poly(vinyl alcohol) and poly(styrene sulfonic acid-co-maleic anhydride) as proton exchange fuel cell membranes,” Journal of Power Sources, vol. 164, no. 2, pp. 449–456, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Google Scholar · View at Scopus
  45. T. Zor and Z. Selinger, “Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies,” Analytical Biochemistry, vol. 236, no. 2, pp. 302–308, 1996. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Scheuch and R. Siekmeier, “Novel approaches to enhance pulmonary delivery of proteins and peptides,” Journal of Physiology and Pharmacology, vol. 58, no. 5, pp. 615–625, 2007. View at Google Scholar · View at Scopus
  47. L. A. Dailey, T. Schmehl, T. Gessler et al., “Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features,” Journal of Controlled Release, vol. 86, no. 1, pp. 131–144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Grenha, B. Seijo, and L. Remuñán-López, “Microencapsulated chitosan nanoparticles for lung protein delivery,” European Journal of Pharmaceutical Sciences, vol. 25, pp. 427–437, 2005. View at Google Scholar
  49. R. D. Shannon, “Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides,” Acta Crystallographica, vol. 32, pp. 75l–767, 1976. View at Google Scholar
  50. S. Sakuma, H. Ohshima, and T. Kondo, “Charge distribution in poly(N,N-l-lysinediylterephthaloyl) microcapsule membranes,” Journal of Colloid And Interface Science, vol. 133, no. 1, pp. 253–256, 1989. View at Google Scholar · View at Scopus
  51. S. Sakuma, H. Ohshima, and T. Kondo, “Binding constants of metal cations to and hamaker constant for poly(N,N-l-lysinediylterephthaloyl) microcapsules,” Journal of Colloid And Interface Science, vol. 135, no. 2, pp. 455–460, 1990. View at Google Scholar · View at Scopus
  52. H. D. Niall, H. T. Keutmann, D. H. Copp, and J. T. Potts Jr., “Amino acid sequence of salmon ultimobranchial calcitonin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 64, no. 2, pp. 771–778, 1969. View at Google Scholar · View at Scopus
  53. N. A. Peppas and P. A. Buri, “Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues,” Journal of Controlled Release, vol. 2, pp. 257–275, 1985. View at Google Scholar · View at Scopus
  54. H. Takeuchi, H. Yamamoto, T. Niwa, T. Hino, and Y. Kawashima, “Enteral absorption of insulin in rats from mucoadhesive Chitosan-Coated liposomes,” Pharmaceutical Research, vol. 13, no. 6, pp. 896–901, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Illum, N. F. Farraj, and S. S. Davis, “Chitosan as a novel nasal delivery system for peptide drugs,” Pharmaceutical Research, vol. 11, no. 8, pp. 1186–1189, 1994. View at Publisher · View at Google Scholar · View at Scopus
  56. H. L. Lueßen, B. J. de Leeuw, M. W. E. Langemeÿer, A. G. de Boer, J. C. Verhoef, and H. E. Junginger, “Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo,” Pharmaceutical Research, vol. 13, no. 11, pp. 1668–1672, 1996. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Takeuchi, Y. Matsui, H. Yamamoto, and Y. Kawashima, “Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats,” Journal of Controlled Release, vol. 86, no. 2-3, pp. 235–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Takeuchi, Y. Shimotori, H. Yamamoto, T. Hino, and Y. Kawashima, “Protective effects of chitosan and liposomal formulation for enzymatic degradation of insulin and their absorption promoting effects in intestinal mucous layer,” Drug Delivery Systems, vol. 12, pp. 347–352, 1997. View at Google Scholar
  59. T. Morita, A. Yamamoto, Y. Takakura, L. M. Hashida, and H. Sezaki, “Improvement of the pulmonary absorption of (Asu1,7)-eel calcitonin by various protease inhibitors in rats,” Pharmaceutical Research, vol. 11, no. 6, pp. 909–913, 1994. View at Publisher · View at Google Scholar · View at Scopus